Ultrasonic Method for Testing Anti Sickling Agents

超声波法测试抗镰状化剂

• 批准号: 6404660
• 负责人: MARTIN Carl BARUCH
• 金额: $ 30.15万
• 依托单位: EMPIRICAL TECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6404660
• 关键词: bioimaging /biomedical imaging; biomedical equipment development; diagnostic tests; drug screening /evaluation; hemoglobin Ss; human subject; patient oriented research; sickle cell anemia; sickling inhibitor; technology /technique development; viscosity

DESCRIPTION (provided by applicant): The results of the Phase I effort, during the course of which the blood samples of 7 HbSS patients were examined, established the feasibility of using phase-sensitive acoustic detection techniques to quantitatively monitor the polymerization of HbSS. The effects of introducing anti-sickling agents were also clearly resolved in the results. In addition, the acoustic measurements performed on 5 normal blood samples revealed the techniques sensitivity by demonstrating the reproducible resolution of the minute acoustic response to de-oxygenation of normal blood. With the basic response question settled, the primary aim of the Phase II effort will be to develop a laboratory prototype that can be used by a third party to support anti-sickling drug research efforts, general sickle cell research, as well as be potentially used as a potential diagnostic tool in clinical settings. In order to accomplish this goal, the following specific aims will be pursued under Phase II: 1. An improved experimental prototype will be designed. 2. A stable and repeatable test substrate (cell suspension) will be developed. 3. The device will be characterized extensively with regard to calibration, sensitivity, and sample variability. 4. The effects of an extensive number of anti-sickling agents will be measured. PROPOSED COMMERCIAL APPLICATION: Not Available

描述（由申请人提供）：第一阶段工作的结果， 检查7例HbSS患者的血液样品的过程， 建立了使用相敏声波检测的可行性 技术来定量监测HbSS的聚合。的影响 引入抗镰状化剂也在结果中得到明确解决。在 此外，对5个正常血液样本进行声学测量， 通过证明可重复性， 对正常血液脱氧的微小声学响应的分辨率。 在解决了基本的响应问题之后，第二阶段的主要目标 我们将努力开发一个实验室原型， 支持抗镰状细胞病药物研究工作的政党， 研究，以及作为潜在的诊断工具， 临床环境。为了实现这一目标，以下具体 将在第二阶段实现目标：1。一个改进的实验原型将 被设计。2.稳定且可重复的试验基质（细胞悬液）将 发展。3.该器械将在以下方面进行广泛表征： 校准、灵敏度和样品可变性。4.的效果 将测量大量的抗镰状化剂。 拟定商业应用： 不可用